Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences ( (TLSA) ) has shared an announcement.
On September 9, 2025, Tiziana Life Sciences announced that its CEO, Ivor Elrifi, purchased 193,848 shares of the company’s common stock at $1.65 per share. This move underscores confidence in the company’s strategic direction, particularly in advancing its lead candidate, intranasal foralumab, which is undergoing trials for treating non-active secondary progressive multiple sclerosis. This development could potentially enhance Tiziana’s market position and stakeholder confidence in its innovative therapeutic approaches.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical development for treating neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 345,441
Technical Sentiment Signal: Buy
Current Market Cap: $185M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.